Impact of DNA‐Methylation Age Acceleration on Long‐Term Mortality Among US Adults With Cardiovascular‐Kidney‐Metabolic Syndrome
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.039751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Shuang Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing People's Repu…. Hauptthemen laut MEDLINE: Metabolic Syndrome, DNA Methylation, Cardio-Renal Syndrome, Cardiovascular Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The association between DNA methylation age acceleration (DNAmAA) and cardiovascular‐kidney‐metabolic (CKM) syndrome stages and long‐term mortality in the population with CKM syndrome remains unclear. Methods and Results This cohort study included 1889 participants from the National Health and Nutrition Examination Survey (1999–2002) with CKM stages and DNA methylation age data. DNAmAA was calculated as residuals from the regression of DNA methylation age on chronological age. The primary outcome was all‐cause mortality, with cardiovascular and noncardiovascular mortality as secondary outcomes. Proportional odds models assessed the associations between DNAmAAs and CKM stages, and Cox proportional hazards regression models estimated the associations between DNAmAAs and mortality. Significant associations were found between DNAmAAs and advanced CKM stages, particularly for GrimAge2Mort acceleration (GrimAA) (odds ratio [OR], 1.547 [95% CI, 1.316–1.819]). Over an average follow‐up of 14 years, 1015 deaths occurred. Each 5‐unit increase in GrimAA was associated with a 50% increase in all‐cause mortality (95% CI, 1.39–1.63), a 77% increase in cardiovascular mortality (95% CI, 1.46–2.15), and a 42% increase in noncardiovascular mortality (95% CI, 1.27–1.59). With the lowest GrimAA tertile as a reference, the highest GrimAA tertile showed hazard ratios of 1.95 (95% CI, 1.56–2.45) for all‐cause mortality, 3.06 (95% CI, 2.13–4.40) for cardiovascular mortality, and 1.65 (95% CI, 1.20–2.29) for noncardiovascular mortality. Mediation analysis indicated that GrimAA mediates the association between various exposures (including physical activity, Healthy Eating Index‐2015 score, hemoglobin A1c, etc.) and mortality.
Conclusions
GrimAA may serve as a valuable biomarker for assessing CKM stages and mortality risk in individuals with CKM syndrome, thereby informing personalized management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Center for Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing People's Republic of China.
- National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing People's Republic of…
- Liverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart and Chest Hospital Liverpool UK.
- Department of Musculoskeletal Ageing and Science, Institute of Life Course and Medical Sciences University of Liverpool Liverpool UK.
- Department of Cardiovascular Medicine, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi People's Republic of China.
- Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences and Peking Union Medical College Beijing People's Republic of China.
ORCID-Profile: Ziyi Zhong, Hongyu Liu, Lihui Zheng, Yang Chen
Zitieren
APA
Wu, S., Zhu, J., Lyu, S., Wang, J., Shao, X., Zhang, H., Zhong, Z., Liu, H., Zheng, L., & Chen, Y. (2025). Impact of DNA‐Methylation Age Acceleration on Long‐Term Mortality Among US Adults With Cardiovascular‐Kidney‐Metabolic Syndrome. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039751
Vancouver
Wu S, Zhu J, Lyu S, Wang J, Shao X, Zhang H, et al. Impact of DNA‐Methylation Age Acceleration on Long‐Term Mortality Among US Adults With Cardiovascular‐Kidney‐Metabolic Syndrome. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039751
BibTeX
@article{Wu2025,
author = {Wu, Shuang and Zhu, Jun and Lyu, Siqi and Wang, Juan and Shao, Xinghui and Zhang, Han and Zhong, Ziyi and Liu, Hongyu and Zheng, Lihui and Chen, Yang},
title = {Impact of DNA‐Methylation Age Acceleration on Long‐Term Mortality Among US Adults With Cardiovascular‐Kidney‐Metabolic Syndrome},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.039751}
}
EUVIMED